Pacific released a research report on April 25 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) Q1 revenue was under pressure for a short time, and performance achieved relatively rapid growth; 2) the company's net interest rate continued to improve and profitability continued to increase; 3) the reserves of ongoing research projects are abundant, which are expected to continue to contribute to incremental revenue. (Mainichi Keizai Shimbun)
太平洋4月25日发布研报称，给予福元医药（601089.SH）买入评级。评级理由主要包括：1）Q1收入短暂承压，业绩实现较快增长；2）公司净利率持续改善，盈利能力不断提升；3）在研项目储备丰富，有望持续贡献增量收入。（每日经济新闻）
Pacific released a research report on April 25 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) Q1 revenue was under pressure for a short time, and performance achieved relatively rapid
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.